Mechanisms of Leukocyte Regulation by Complement-Derived Factors

  • Tony E. Hugli
  • Edward L. Morgan
Chapter
Part of the Contemporary Topics in Immunobiology book series (CTI, volume 14)

Abstract

As early as the mid-1960s it was recognized that factors derived from the blood complement system could stimulate leukocytes and promote directed leukocyte migration (Ward et al., 1965, 1967; Shin et al., 1968; Snyderman et al., 1968). Shortly thereafter assignments were made that identified anaphylatoxins as the humoral chemotactic factors in question (Jensen et al., 1969; Hill and Ward, 1969; Ward 1967, 1969; Cochrane and Müller-Eberhard, 1968; Fernandez et al., 1978). Anaphylatoxins are low-molecular-weight fragments released from serum components C3, C4, and C5 when the complement cascade is activated; these fragments have been designated C3a, C4a, and C5a, respectively. Several recent reviews describe the properties of the anaphylatoxins in great detail (Hugli and Müller-Eberhard, 1978; Hugli, 1978, 1981, 1982). Before the anaphylatoxins were identified as chemotaxins, they were noted primarily for their spasmogenic and permeability-enhancing activities, mediated largely via vasoamines released from the mast cell (Johnson et al., 1975). However, it was the recognition of neutrophil-anaphylatoxin interactions, using chemotaxis as an indicator of cellular activation, that prompted discovery of numerous other leukocyte responses mediated by these anaphylatoxins. The current status of our knowledge concerning the multiple effects of the anaphylatoxins on leukocyte function is the subject of this chapter.

Keywords

Antibody Response Proliferative Response Chemotactic Factor Chemotactic Activity Human Peripheral Blood Lymphocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beebe, D. P., Ward, P. A., and Spitznagel, S. K., 1980, Isolation and characterization of acidic chemotactic factor from complement activated human serum, Clin. Immunol. Immunopathol. 15:88–105.PubMedGoogle Scholar
  2. Berenberg, J. L., and Ward, P. A., (1973), The chemotactic factor inactivator in normal human serum, J. Clin Invest. 52:1200–1206.PubMedGoogle Scholar
  3. Boetcher, D. A., and Leonard, E. J., 1973, Basophil chemotaxis: Augmentation by a factor from stimulated lymphocyte cultures, Immunol. Commun. 2(4):421–429.PubMedGoogle Scholar
  4. Bokisch, V. A., and Müller-Eberhard, H. J., 1970, Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase, J. Clin. Invest. 49: 2427–2436.PubMedGoogle Scholar
  5. Bokisch, V. A., Mü ller-Eberhard, H. J., and Cochrane, C. G., 1969, Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum, J. Exp. Med. 129:1109–1130.PubMedGoogle Scholar
  6. Boyden, S., 1962, The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes, J. Exp. Med. 115:453–466.PubMedGoogle Scholar
  7. Burger, R., and Schvach, E. M., 1979, Evaluation of the role of C4 in the cellular immune response in vitro, J. Immunol. 122:2388–2394.PubMedGoogle Scholar
  8. Caporale, L. H., Tippett, P. S., Erickson, B. W., and Hugli, T. E., 1980, The active site of C3a anaphylatoxin, J. Biol. Chem. 255:10758–10763.PubMedGoogle Scholar
  9. Chenoweth, D., and Hugli, T. E., 1978, Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes, Proc. Natl. Acad. Sci. USA 75:3943–3947.PubMedGoogle Scholar
  10. Chenoweth, D. E., and Hugli, T. E., 1980a, Human C5a and C5a analogs as probes of the neutrophil C5a receptor, Mol. Immunol. 17:151–161.PubMedGoogle Scholar
  11. Chenoweth, D. E., and Hugli, T. E., 1980b, Binding, internalization and degradation of human C5a by human neutrophils, Fed. Proc. 39:1049.Google Scholar
  12. Chenoweth, D. E., Rowe, J. B., and Hugli, T. E., 1979, A modified method for chemotaxis under agarose, J. Immunol. Methods 25:337–353.PubMedGoogle Scholar
  13. Chenoweth, D. E., Cooper, S. W., Hugli, T. E., Stewart, R. W., Blackstone, E. H., and Kirklin, J. W., 1981, Complement activation during cardiopulmonary bypass, N. Engl. J. Med. 304:497–503.PubMedGoogle Scholar
  14. Clancy, R. M., Dahinden, C. A., and Hugli, T. E., 1983, Arachidonate metabolism by human polymorphonuclear leukocytes stimulated by N-formyl peptide or C5a is independent of phopholipase activation, Proc. Natl. Aca. Sci. 80:7200–7204.Google Scholar
  15. Cochrane, C. G., and Müller-Eberhard, H. J., 1968, The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement, J. Exp. Med. 127:371–386.PubMedGoogle Scholar
  16. Craddock, P. R., Hammerschmidt, D. E., White, J. G., and Jacob, H. S., 1976, Granulocyte (PMN) aggregometry-a new technique for the study of complement and C5a effects upon PMNs and their plasma membranes, Blood 48:961–966.Google Scholar
  17. Craddock, P. R., Hammerschmidt, D., White, J. G., Dalmasso, A. P., and Jacob, H. S., 1977a, Complement (C5a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia, J. Clin. Invest. 60:260–264.PubMedGoogle Scholar
  18. Craddock, P. R., Fehr, J., Brigham, K. L., Kronenberg, R., and Jacob, H. S., 1977b, Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis, N. Engl. J. Med. 296:769–776.PubMedGoogle Scholar
  19. Craddock, P. R., White, J. G., and Jacob, H. S., 1978, Potentiation of complement (C5a)induced granulocyte aggregation by cytochalasin B, J. Lab. Clin. Med. 91:490–496.PubMedGoogle Scholar
  20. Craddock, P. R., Hammerschmidt, D. E., Moldow, C. F., Yamada, O., and Jacob, H. S., 1979, Granulocyte aggregation as a manifestation of membrane interactions with complement: Possible role in leukocyte margination, micro-vascular occulsion, and endothelial damage, Semin Hematol. 16:140–194.PubMedGoogle Scholar
  21. Cutler, J. E., 1974, A simple in vitro method for studies on chemotaxis, Proc. Soc. Exp. Biol. Med. 147:471–474.PubMedGoogle Scholar
  22. Dahinden, C. A., Fehr, J., and Hugli, T. E., 1983, Role of cell surface contact on the kinetics of superoxide production by granulocytes, J. Clin. Invest. 72:113–121.PubMedGoogle Scholar
  23. Damerau, B., Zimmerman, B., Wustefeld, H., Czorniak, K., and Vogt, W., 1983, Involvement of the N terminus of HOG C3a, C5a, and C5a-desArg in their biological activities, Immunobiology 164(3/4):229 (abst).Google Scholar
  24. Denny, J. B., and Johnson, A. R.,1979, Uptake of 125 I-labeled C3a by cultured human endothelial cells,Immunology 36:169–177.Google Scholar
  25. Dukor, P., Schumann, G., Gisler, R. H., Dierich, M., Konig, W., Hadding, U., and BitterSuermann, D., 1974, Complement dependent B-cell activation by cobra venom factor and other mitogens, J. Exp. Med. 139:337–354.PubMedGoogle Scholar
  26. Fernandez, H. N., and Hugli, T. E., 1976, Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide portions of human C5a, J. Immunol. 117:1688–1694.PubMedGoogle Scholar
  27. Fernandez, H. N., and Hugli, T. E., 1978, Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. I. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a, J. Biol. Chem. 253:6955–6964.PubMedGoogle Scholar
  28. Fernandez, H. N., Henson, P. M., Otani, A., and Hugli, T. E., 1978, Chemotaxis response to human C3a and C5a anaphylatoxins. I. Evaluations of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions, J. Immunol. 120:109–115.PubMedGoogle Scholar
  29. Ford-Hutchinson, A. W., Bray, M. A., Doing, M. V., Shipley, M. E., and Smith, J. H., 1980, Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes, Nature 286:264–265.PubMedGoogle Scholar
  30. Gallin, J. I., and Quie, P. G. (eds.), 1978, in: Leukocyte Chemotaxis: Methods, Physiology and Clinical Implications, Raven Press, New York.Google Scholar
  31. Gallin, J. I., Clark, R. A., and Kimbal, H. R., 1973, Granulocytes chemotaxis: An improved in vitro assay employing 51 Cr-labeled granulocytes, J. Immunol. 110:233–240.PubMedGoogle Scholar
  32. Gallin, J. I., Durocher, J. R., and Kaplan, A. P., 1975, Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface change, J. Clin. Invest. 55: 967–974.PubMedGoogle Scholar
  33. Gerard, C., and Hugli, T. E., 1979, Anaphylatoxin from the fifth component of porcine complement. I. Purification and partial chemical characterization, J. Biol. Chem. 254: 6346–6351.PubMedGoogle Scholar
  34. Gerard, C., and Hugli, T. E., 1980, Amino acid sequence of the anaphylatoxin f rom t he fifth component of porcine complement, J. Biol. Chem. 255:4710–4715.PubMedGoogle Scholar
  35. Gerard, C., and Hugli, T. E., 1981, Identification of the classical anaphylatoxins C5adesArg: Evidence of a modulator role for the oligosaccharide unit in human C5a, Proc. Natl. Acad Sci. USA 78:1833–1837.PubMedGoogle Scholar
  36. Gerard, C., Chenoweth, D. E., and Hugli, T. E., 1979, Molecular aspects of the serum chemotactic factors, J. Reticuloendothel. Soc. 26:711–718.PubMedGoogle Scholar
  37. Gerard, C., Chenoweth, D. E., and Hugli, T. E., 1981, Response of human neutrophils to C5a: A role of the oligosaccharide moiety of human C5ad es Ar g -74 but not of C5a in biological activity, J. Immunol. 127:1978–1982.PubMedGoogle Scholar
  38. Ghebrehiwet, B., and Müller-Eberhard, H. J., 1979, C3e: An acidic fragment of human C3 with leucocytosis inducing activity, J. Immunol. 123:616–621.PubMedGoogle Scholar
  39. Glovsky, M. M., Hugli, T. E., Ishizaka, T., Lichtenstein, L. M., and Erickson, B. W., 1979, Anaphylatoxin-induced histamine release with human leukocytes: Studies of C3a leukocyte binding and histamine release, J. Clin. Invest. 64:804–811.PubMedGoogle Scholar
  40. Goodman, M. G., Chenoweth, D. E., and Weigle, W. O., 1982, Potentiation of the primary humoral immune response in vitro by C5a anaphylatoxins, J. Immunol. 129:70–75.PubMedGoogle Scholar
  41. Goodman, M. G., Chenoweth, D. E., and Weigle, W. O., 1983, Induction of interleukin-1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors, J. Exp. Med. 156:912–917.Google Scholar
  42. Grant, J. A., Dupree, E., Goldman, A. S., Schultz, D. R., and Jackson, A. L., 1975, Complement mediated release of histamine from human leukocytes, J. Immunol. 114: 1101–1106.PubMedGoogle Scholar
  43. Hammerschmidt, D. E., Craddock, P. R., McCullough, J., Kronenberg, R. S., Dalmasso, A. P., and Jacob, J. S., 1978, Complement activation and pulmonary leukostasis during nylon fiber filtration leukopheresis, Blood 51:721–730.PubMedGoogle Scholar
  44. Hammerschmidt, D. E., Weaver, L. J., Hudson, L. D., Craddock, P. R., and Jacob, H. S., 1980, Association of complement activation and elevated plasma-05a with adult respiratory distress syndrome: Pathophysiological relevance and possible prognostic value, Lancet 1:947–949.PubMedGoogle Scholar
  45. Hartmann, F. U., 1975, Possible involvement of C3 during stimulation of B lymphocytes, Transplant. Rev. 23:98–103.PubMedGoogle Scholar
  46. Hartmann, K. U., and Bokisch, H., 1975, Stimulation of murine B lymphocyte in isolated C3b, J. Exp. Med. 142:600–610.PubMedGoogle Scholar
  47. Heideman, M., and Hugli, T. E., 1984, Anaphylatoxin generation in multisystem organ failure, Trauma (in press).Google Scholar
  48. Hill, J. H., and Ward, P. A., 1969, C3 leukotactic factors produced by a tissue protease, J. Exp. Med. 130:505–518.PubMedGoogle Scholar
  49. Hobbs, M. V., Feldbush, T. L., Needleman, B. W., and Weiler, M. J., 1982, Inhibition of secondary in vitro antibody responses by the third component of complement, J. Immunol. 128:1470–1475.PubMedGoogle Scholar
  50. Hook, W. A., Siraganian, R. P., Wahl, S. M., 1975, Complement induced histamine release from human basophils. Generation of activity in human serum, J. Immunol. 114: 1185–1190.PubMedGoogle Scholar
  51. Huber, R., Scholze, H., Paques, E. P., and Deisenhofer, J., 1980, Crystal structure analysis and molecular model of human C3a anaphylatoxin, Hoppe Seylers Z. Physiol. Chem. 361:1389–1399.PubMedGoogle Scholar
  52. Huey, R., Bloor, C. M., Kawahara, M. S., and Hugli, T. E., 1983, Potentiation of the anaphlytoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and effects on pulmonary tissue. Am. J. Pathol. 112:48–60.PubMedGoogle Scholar
  53. Huey, R., Erickson, B. W., Bloor, C. W., and Hugh, T. E., 1984, Contraction of guinea pig lung by synthetic oligopeptides related to human C3a, Immunopharmacology (submitted).Google Scholar
  54. Hugli, T. E., 1978, Chemical aspects of the serum anaphylatoxins, in: Contemporary Topics in Molecular Immunology, Vol. 7 (R. A. Reisfeld and F. Inman, eds.), pp. 181–214, Plenum Press, New York.Google Scholar
  55. Hugh, T. E., 1981, The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a, in: Critical Reviews in Immunology, I, 4, pp. 321–366, CRC Press Review, Boca Raton, Florida.Google Scholar
  56. Hugli, T. E., 1982, Bioactive factors of the blood complement system in: Proteins in Biology and Medicine, (R. A. Bradshaw, R. L. Hill, and J. Tang, eds.), pp. 91–117, Proceedings of P.R.C.-USA Conference in Shanghai, China, Academic Press.Google Scholar
  57. Hugli, T. E., and Erickson, B. W., 1977, Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin, Proc. Natl. Acad. Sci. USA 74:1826–1830.PubMedGoogle Scholar
  58. Hugli, T. E., and Müller-Eberhard, H. J., 1978, Anaphylatoxins: C3a and C5a, Adv. Immunol. 26:1–48.PubMedGoogle Scholar
  59. Hugli, T. E., Morgan, W. T., and Müller-Eberhard, H. J., 1975, Circular dichroism of C3a anaphylatoxin: Effects of pH, heat, guanidinium and chloride and mercaptoethanol on conformation and function, J. Biol. Chem. 250:1479–1483.PubMedGoogle Scholar
  60. Jensen, J. A., Snyderman, R., and Mergenhagen, S. E., 1969, Chemotactic activity, a property of guinea pig C5-anaphylatoxins, in: Cellular and Humoral Mechanisms in Anaphlaxis and Allergy (H. Z. Movat, ed.), pp. 265–278, S. Karger, New York.Google Scholar
  61. Johnson, A. R., Hugli, T. E., and Müller-Eberhard, H. J., 1975, Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 28:1067–1080.PubMedGoogle Scholar
  62. Kay, A. B., Shin, H. S., and Austen, K. F., 1973, Selective attraction of eosinophils and synergism between eosinophil chemotactic factor of anaphylaxis (ECF-A) and a fragment cleaved from the fifth component of complement (C5a), Immunology 24:969–976.PubMedGoogle Scholar
  63. Koopman, W. J., Sandberg, A. L., Wahl, S. M., and Mergenhagen, S. E., 1976, Interaction of soluble C3 fragments with guinea pig lymphocytes. Comparison of effects of C3a, C3b, C3c, and C3d on lymphokine production and lymphocyte proliferation, J. Immunol. 117:331–336.PubMedGoogle Scholar
  64. Laan, B., Molenaar, J. L., Feltkamp-Vroom, T. M., and Pondman, K. W., 1974, Interaction of human anaphylatoxin C3a with rat mast cells demonstrated by immunofluorescence, Eur. J. Immunol. 4:393–395.PubMedGoogle Scholar
  65. Lackie, J. M., 1977, The aggregation of rabbit polymorphonuclear leukocytes (PMNs) : Effects of agents which affect the acute inflammatory response and correlation with secretory activity, Inflammation 2:1–15.PubMedGoogle Scholar
  66. Mackler, B. F., Altman, L. C., Rosenstreich, D. L., and Oppenheim, J. J., 1974, Induction of lymphokine production by EAC and of blastogenesis by soluble mitogens during human B-cell activation, Nature 249:834–837.PubMedGoogle Scholar
  67. Maderazo, E. G., and Woronich, C. L., 1978, Micropore filter assay of human granulocyte locomotion: Problems and solutions, Clin. Immunol. Immunopathol. 11:196–211.Google Scholar
  68. Maderazo, E. G., Ward, P. A., and Quintilliani, R., 1975, Defective regulation of chemotaxis in cirrhosis, J. Lab. Clin. Med. 85:621–624.PubMedGoogle Scholar
  69. Maderazo, E. G., Ward, P. A., Woronick, C. L., Kubik, J., and DeGraff, A. C., 1976, Leukotactic dysfunction in sarcoidosis, Ann Intern. Med. 84:414–417.PubMedGoogle Scholar
  70. Malmsten, C. L., Palmblad, J., Uden, A.-M., Radmark, O., Engstedt, L., and Samuelsson, B. 1980, Leukotriene B4 : A highly potent and stereospecific factor stimulating migration of polymophonuclear leukocytes, Acta Physiol. Scand. 110:449–451.PubMedGoogle Scholar
  71. Martinelli, G. P., Matsuda, T., and Osler, A. G., 1978, Studies on immunosuppression by cobra venom factor. I. An early IgG and IgM response to sheep erythrocyte and DNPprotein conjugates, J. Immunol. 121:2043–2047.PubMedGoogle Scholar
  72. Meuth, J. L., Morgan, E. L., DiScipio, R. G., and Hugli, T. E., 1983, Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b, J. Immunol. 130: 2605–2611.PubMedGoogle Scholar
  73. Morgan, E. L., and Weigle, W. O., 1979, Macrophage requirement in the Fc fragmentinduced proliferative response of murine spleen cells, J. Exp. Med. 150:256–266.PubMedGoogle Scholar
  74. Morgan, E. L., and Weigle, W. O., 1980a, Regulation of Fc fragment-induced murine spleen cell proliferation, J. Exp. Med. 151:1–11.PubMedGoogle Scholar
  75. Morgan, E. L., and Weigle, W. O., 1980b, Polyclonal activation of murine B lymphocytes by Fc fragments. I. The requirement for two signals in the generation of the polyclonal antibody response induced by Fc fragments, J. Immunol. 124:1330–1335.PubMedGoogle Scholar
  76. Morgan, E. L., and Weigle, W. O., 1980c, Regulation of B lymphocyte activation by the Fc portion of immunoglobulin, J. Supramol. Struct. 14:201–208.PubMedGoogle Scholar
  77. Morgan, E. L., and Weigle, W. O., 1981, Polyclonal activation of human B lymphocytes by Fc fragments for Fc fragment-mediated polyclonal antibody secretion by human peripheral blood lymphocytes, J. Exp. Med. 154:778–790.PubMedGoogle Scholar
  78. Morgan, E. L., Weigle, W. O., and Hugli, T. E., 1982, Anaphylatoxin mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses, J. Exp. Med. 155:1412–1426.PubMedGoogle Scholar
  79. Morgan, E. L., Thoman, M. L., Weigle, W. O., and Hugli, T. E., 1983a, Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses, J. Immunol. 130:1257–1266.PubMedGoogle Scholar
  80. Morgan, E. L., Weigle, W. O., Erickson, B. W., Fok, K-F, and Hugli, T. E., 1983b, Suppression of humoral immune responses by synthetic C3a peptides, J. Immunol. 131: 2258–2261.PubMedGoogle Scholar
  81. Morgan, E. L., Thoman, M. L., Weigle, W. O., and Hugli, T. E., 1984. Human C3a-mediated suppression of the immune response. I. Suppression of human and murine in vitro antibody response occurs through the generation of nonspecific suppressor T cells. J. Immunol. (submitted).Google Scholar
  82. Mosier, D. E., Scher, I., and Paul, W. E., 1976, In vitro responses of CBA/N mice: Spleen cells of mice with an X-linked defect that precludes immune responses to several thymus-independent antigens can respond to TNP-lipopolysaccharide, J. Immunol. 117:1363–1369.PubMedGoogle Scholar
  83. Needleman, B. M., Weiler, J. M., and Feldbush, T. L., 1981, The third component of complement inhibits human lymphocyte blastogenesis, J. Immunol. 125:1586–1589.Google Scholar
  84. Nelson, R. D., Quie, P. G., and Simons, R. L., 1975, Chemotaxis under agarose: A new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes, J. Immunol. 115:1650–1656.PubMedGoogle Scholar
  85. O’Flaherty, J. T., and Ward, P. A., 1978, Leukocyte aggregation induced by chemotactic factors, Inflammation 3:177–194.PubMedGoogle Scholar
  86. O’Flaherty, J. T., Kreutzer, D. L., and Ward, P. A., 1977a, Neutrophil aggregation and swelling induced by chemotactic agents, J. Immunol. 119:232–239.PubMedGoogle Scholar
  87. O’Flaherty, J. T., Kreutzer, D. L., Showell, H. J., and Ward, P. A., 1977b, Influence of inhibitors of cellular function on chemotactic factor induced neutrophil aggregation, J. Immunol. 119:1751–1756.PubMedGoogle Scholar
  88. O’Flaherty, J. T., Kreutzer, D. L., and Ward, P. A., 1978, Chemotactic factor influences on the aggregation, swelling and foreign surface adhesiveness of human leukocytes, Am. J. Pathol. 90:537–550.PubMedGoogle Scholar
  89. Ondetti, M. A., Condon, M. E., Reid, J., Sabo, E. F., Cheung, H. S., and Cushman, D. W., 1979, Design of potent and specific inhibitors of carboxypeptidases A and B, Biochemistry 18:1427–1430.PubMedGoogle Scholar
  90. Orr, W., and Ward, P. A., 1978, Quantitation of leukotaxis in agarose by three different methods, J. Immunol. Methods 20:95–107.PubMedGoogle Scholar
  91. Payan, D. G., Trentham, D. E., and Goetzl, E. J., 1982, Modulation of human lymphocyte function by C3a and C3a (70–77), J. Exp. Med. 156:756–765.PubMedGoogle Scholar
  92. Pepys, M. D., and Butterworth, A. F., 1974, Inhibitions by C3 fragments of C3-dependent rosette formation and antigen-induced lymphocyte transformation, Clin. Exp. Immunol. 18:273–280.PubMedGoogle Scholar
  93. Pepys, M. B., 1976, Role of complement in the induction of immunological responses, Transplant. Rev. 32:93.PubMedGoogle Scholar
  94. Pepys, M. B., Mujah, D. D., and Dash, A. C., 1976, Immunosuppression by cobra venom factor: Distribution, antigen-induced blast transformation and trapping of lymphocyte during in vivo complement depletion, Cell. Immunol. 21:327–336.PubMedGoogle Scholar
  95. Perez, H. D., Goldstein, I. M., Chernoff, D., Webster, R. O., and Henson, P. M., 1980, Chemotactic activity of C5adesArg: Evidence of a requirement for an anionic peptide “Helper factor” and inhibition by a cationic protein in serum from patients with systemic lupus erythematous, Mol. Immunol. 17:163–169.PubMedGoogle Scholar
  96. Plummer, T. H., and Hurwitz, N. Y., 1978, Human plasma carboxypeptidase N, J. Biol. Chem. 253:3907–3912.PubMedGoogle Scholar
  97. Reinherz, E. L., Kung, P. C., Goldstein, G., and Schlossman, S. F., 1979, Further characterization of the human inducer T cell subset defined by monoclonal antibody, J. Immunol. 123:2894–2896.PubMedGoogle Scholar
  98. Romball, C. G., Ulevitch, R. J., and Weigle, W. O., 1980, role of C3 in the regulation of a splenic PFC response in rabbits, J. Immunol. 124:151–155.Google Scholar
  99. Ross, G. D., and Newman, S. L., 1984, Macrophage function by complement, complement receptor, and IgG-Fc receptors, in: The Reticuloendothelial System: A Comprehensive Treatise, Vol. 6 (J. A. Bellanti and H. D. Herscowitz, eds.), pp. 87–112, Plenum Press, New York.Google Scholar
  100. Rother, K., 1972, Leukocyte mobilizing factor: A new biological activity derived from the third component of complement, Eur. J. Immunol. 2:550–558.PubMedGoogle Scholar
  101. Sacks, T., Moldow, C. F., Craddock, P. R., Bowers, T. K., and Jacob, H. S., 1978, Oxygen radicals mediate endothelial damage by complement-stimulated granulocytes: An in vitro model of immune vascular damage, J. Clin. Invest. 61:1161–1167.PubMedGoogle Scholar
  102. Schenkein, H. A., and Genco, R. H., 1979, Inhibition of lymphocyte blastogenesis by C3c and C3d, J. Immunol. 122:1126–1133.PubMedGoogle Scholar
  103. Scher, I., Steinberg, A. D., Benning, A. K., and Paul, W. E., 1975, X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect, J. Exp. Med. 142:637–650.PubMedGoogle Scholar
  104. Shaw, J. O., Henson, P. M., Henson, J., and Webster, R. O., 1980, Lung inflammation induced by complement-derived chemotactic fragments in the alveolus, Lab. Invest. 42:547–558.PubMedGoogle Scholar
  105. Shin, H. S., Snyderman, R., Friedman, E., Mellors, A., and Mayer, M. M., 1968, Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig, Science 162:361–363.PubMedGoogle Scholar
  106. Siraganian, R. P., and Hook, W. A., 1976, Complement induced histamine release from human basophils. II. Mechanisms of the histamine reaction, J. Immunol. 116:639–646.PubMedGoogle Scholar
  107. Snyderman, R., Gewruz, H., and Mergenhagen, S. E., 1968, Interactions of the complement system with endotoxic lipopolysaccharide, J. Exp. Med. 128:259–275.PubMedGoogle Scholar
  108. Snyderman, R., Shin, H. S., Phillips, J. K., Gewruz, H., and Mergenhagen, S. E., 1969, AGoogle Scholar
  109. neutrophil chemotactic factor derived from C’5 upon interaction of guinea pig serum with endotoxin, J. Immunol. 103:413–422.Google Scholar
  110. Snyderman, R., Altman, L. C., Hausman, M. S., and Mergenhagen, S. E., 1972, Human mononuclear leukocyte chemotaxis: A quantitative assay for humoral and cellular chemotactic factors, J. Immunol. 108:857–860.PubMedGoogle Scholar
  111. Stimler, N. P., Bach, M. K., Bloor, C. M., and Hugli, T. E., 1982, Release or leukotrienes from guinea pig lung stimulated by C5adesArg anaphylatoxin, J. Immunol. 128: 2247–2252.PubMedGoogle Scholar
  112. Thoman, M. L., Morgan, E. L., and Weigle, W. O., 1980a, Activation of T lymphocytes by the Fc position of immunoglobulin, J. Supramol. Struct. 13:479–486.PubMedGoogle Scholar
  113. Thoman, M. L., Morgan, E. L., and Weigle, W. O., 1980b, Polyclonal activation of murine B lymphocytes by Fc fragments. II. Replacement of T cells by a soluble helper T cellreplacing factor (TRF), J. Immunol. 125:1630–1633.PubMedGoogle Scholar
  114. Thoman, M. L., Morgan, E. L., and Weigle, W. O., 1981, Fc fragment activation of T lymphocyte. I. Fc fragments trigger Lyti 2+3- T lymphocytes to release a helper T cellreplacing factor, J. Immunol. 126:632–635.PubMedGoogle Scholar
  115. Till, G., and Ward, P. A., 1975, Two distinct chemotactic factor inactivators in human serum, J. Immunol. 114:834–847.Google Scholar
  116. Vallota, E. H., and Müller-Eberhard, H. J., 1973, Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator, J. Exp. Med. 137:1109–1123.PubMedGoogle Scholar
  117. Vallota, E. H., Hugli, T. E., and Müller-Eberhard, H. J., 1973, Isolation and characterization of a new and highly active form of C5a anaphylatoxin from epsilon-aminocaproic acidcontaining porcine serum, J. Immunol. 111:294 (abst).Google Scholar
  118. Wahl, S. M., Iverson, G. M., and Oppenheim, J. J., 1974, Induction of guinea pig B-cell lymphokine synthesis by mitogenic and nonmitogenic signals to Fc, Ig, and C3 receptors, J. Exp. Med. 140:1631–1645.PubMedGoogle Scholar
  119. Ward, P. A., 1967, A plasmin-split fragment of C’3 as a new chemotactic factor, J. Exp. Med. 126:189–206.PubMedGoogle Scholar
  120. Ward, P. A., 1969, The heterogeneity of chemotactic factors for neutrophils generated from the complement system, in: Cellular and Humoral Mechanisms in Anaphylaxis and Allergy (N. Movat, ed.), pp. 279–310, S. Karger, Basel, New York.Google Scholar
  121. Ward, P. A., and Becker, E. L., 1976, Biology of Leukotaxis, Rev. Physiol. Biochem. Pharmacol. 77:125–148.Google Scholar
  122. Ward, P. A., and Berenberg, J. L., 1974, Defective regulation of inflammatory mediators in Hodgkin’s disease. Supernormal levels of chemotactic factor inactivator, N. Engl. J. Med. 290: 76–78.PubMedGoogle Scholar
  123. Ward, P. A., and Newman, L. J., 1969, A neutrophil chemotactic factor from Human C5, J. Immunol. 102:93–99.PubMedGoogle Scholar
  124. Ward, P. A., Cochrane, C. G., and Müller-Eberhard, H. J., 1965, The role of serum complement of chemotaxis pf PMNs, J. Exp. Med. 122:327–346.PubMedGoogle Scholar
  125. Ward, P. A., Cochrane, C. G., and Müller-Eberhard, H. J., 1967, Further studies on the chemotactic factor of complement and its formation in vivo, Immunology 11:141–153.Google Scholar
  126. Ward, P. A., Dvorak, H. F., Cohen, S., Yoshida, T., Data, R., and Selvaggio, S. S., 1975, Chemotaxis of basophils by lymphocyte-dependent and lymphocyte-independent mechanisms, J. Immunol. 114:1523–1531.PubMedGoogle Scholar
  127. Ward, P. A., Goralnick, S., and Bullock, W. E., 1976, Defective leukotaxis in patients with lepromatous leprosy, J. Lab. Clin. Med. 87:1025–1029.PubMedGoogle Scholar
  128. Webster, R. O., Hong, S. R.,Johnston Jr., R. B., and Henson, P. M., 1980, Biological effects of the human complement fragments C5a and C5ade s Arg on neutrophil function, Immunopharmacology 2: 201–219.PubMedGoogle Scholar
  129. Weiler, J. M., Ballas, Z. B., Needleman, B. W., Hobbs, M. W., and Feldbush, T. L., 1982, Complement fragments suppress lymphocyte immune responses, Immunol. Today 3: 738–743.Google Scholar
  130. Wilkinson, P. C., 1974, Chemotaxis and Inflammation, Churchill-Livingstone, Edinburgh, Scotland.Google Scholar
  131. Wissler, J. H., Stecher, V. J., and Sorkin, E., 1972, Biochemistry and biology of a leucotactic binary serum peptide system related to anaphylatoxin, Int. Arch. Allergy Appl. Immunol. 42:722–728.PubMedGoogle Scholar
  132. Zigmond, S. H., 1980, Polymorphonuclear leucocyte chemotaxis: Detection of the gradient and development of cell polarity, Ciba Found. Symp. 71:299–311.PubMedGoogle Scholar
  133. Zigmond, S. H., and Hirsch, H. G., 1973, Leukocyte locomotion and chemotaxis: New methods for evaluation, and demonstration of a cell-derived chemotactic factor, J. Exp. Med. 137:387–410.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • Tony E. Hugli
    • 1
  • Edward L. Morgan
    • 1
  1. 1.Department of ImmunologyScripps Clinic and Research FoundationLa JollaUSA

Personalised recommendations